Generate Investment Management Ltd Sells 21,383 Shares of AbbVie Inc. $ABBV

Generate Investment Management Ltd lowered its holdings in AbbVie Inc. (NYSE:ABBV) by 38.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 34,188 shares of the company’s stock after selling 21,383 shares during the quarter. Generate Investment Management Ltd’s holdings in AbbVie were worth $8,943,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of ABBV. ACT Advisors LLC. grew its stake in shares of AbbVie by 2.5% in the second quarter. ACT Advisors LLC. now owns 1,688 shares of the company’s stock worth $425,000 after acquiring an additional 41 shares during the period. Willner & Heller LLC boosted its holdings in AbbVie by 0.7% in the second quarter. Willner & Heller LLC now owns 5,852 shares of the company’s stock worth $1,472,000 after purchasing an additional 43 shares during the last quarter. B.O.S.S. Retirement Advisors LLC grew its position in AbbVie by 3.1% in the 2nd quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company’s stock worth $359,000 after purchasing an additional 43 shares during the period. Fielder Capital Group LLC grew its position in AbbVie by 1.7% in the 2nd quarter. Fielder Capital Group LLC now owns 2,532 shares of the company’s stock worth $637,000 after purchasing an additional 43 shares during the period. Finally, Guardian Wealth Advisors LLC NC raised its stake in AbbVie by 0.4% during the 2nd quarter. Guardian Wealth Advisors LLC NC now owns 11,906 shares of the company’s stock valued at $2,996,000 after buying an additional 43 shares during the last quarter. 70.23% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. The trade was a 30.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.06% of the stock is owned by insiders.

Analysts Set New Price Targets

Several analysts recently commented on the company. Scotiabank lifted their price objective on AbbVie from $280.00 to $320.00 and gave the stock an “outperform” rating in a report on Tuesday, October 6th. Wolfe Research raised AbbVie from a “peer perform” rating to an “outperform” rating and increased their target price for the company from $235.00 to $300.00 in a report on Thursday, August 13th. BMO Capital Markets raised their target price on AbbVie from $258.00 to $300.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Weiss Ratings upgraded AbbVie from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, October 8th. Finally, UBS Group upped their price target on shares of AbbVie from $260.00 to $275.00 and gave the company a “neutral” rating in a research report on Tuesday, October 6th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $277.18.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Positive SKYRIZI Crohn’s disease data: New Phase 3 AFFIRM results showed that subcutaneous SKYRIZI generated higher clinical and endoscopic response rates than placebo in adults with moderately to severely active Crohn’s disease. The data strengthen the outlook for AbbVie’s leading immunology franchise and its ability to support long-term growth. AbbVie’s Crohn’s Disease Drug SKYRIZI Shows More Positive Results
• Positive Sentiment: Growth engines remain in focus: Recent SKYRIZI and RINVOQ updates have reinforced expectations that the therapies can offset Humira’s continuing decline. RBC also expects the products, along with Vraylar, to support a potential third-quarter revenue beat. AbbVie Poised for Q3 Top-Line Beat
• Positive Sentiment: Supportive analyst backdrop: Royal Bank of Canada reaffirmed its outperform rating, while Erste Group raised its FY2027 EPS forecast to $16.34 from $16.19 and maintained a Buy rating. These actions add to investor confidence ahead of earnings.
• Neutral Sentiment: Institutional interest is mixed: Recent filings showed substantial buying by several large institutions, although other investors reduced their positions. One AbbVie executive also sold shares, but the transaction does not appear to be a central driver of the session.
• Negative Sentiment: Valuation and execution risks remain: AbbVie trades near its 52-week high, and some valuation analysis suggests the shares may be ahead of estimated fair value. Investors also remain focused on Humira erosion, competition in immunology, and the company’s elevated growth expectations.

AbbVie Stock Performance

Shares of AbbVie stock traded up $9.69 during trading hours on Wednesday, hitting $284.05. The company’s stock had a trading volume of 1,608,315 shares, compared to its average volume of 6,389,302. The company has a market cap of $501.85 billion, a PE ratio of 80.27, a PEG ratio of 1.28 and a beta of 0.24. The business has a 50 day moving average price of $260.41 and a two-hundred day moving average price of $237.87. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $284.64.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. AbbVie’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, research analysts anticipate that AbbVie Inc. will post 13.95 earnings per share for the current year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s payout ratio is presently 195.48%.

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.